SCHEMBL2109299

SCHEMBL2109299

CCOc1oc2ccccc2c(=O)c1-c1ccccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ C1R P00736 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ PLK3 Q9H4B4 1/20 0.41
▸ CYP2C9 P11712 3/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ KDM4E B2RXH2 6/20 0.39
▸ HPGD P15428 4/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HTT P42858 1/20 0.38
▸ MAOA P21397 3/20 0.37
▸ ABCB1 P08183 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2109294 0.81 KDM4E (0.50) NTRK1PLK3CYP2C9MAPTTP53
SCHEMBL27934332 0.78 CA1 (0.55) CYP2C9CYP2A6MAPTTP53RXFP1
SCHEMBL2109297 0.76 ADORA3 (0.39) CYP2C9CYP2A6MAPTTP53KDM4E
SCHEMBL8521476 0.75 ALDH1A1 (0.44) CYP2C9MAPTKDM4EHPGDALDH1A1
SCHEMBL896578 0.68 KDM4E (0.63) C1RNTRK1PLK3CYP2C9MAPT
SCHEMBL8983913 0.68 CA1 (0.52) CYP2C9CYP2A6MAPTTP53KDM4E
SCHEMBL11104393 0.67 KDM4E (0.54) NTRK1PLK3CYP2C9CYP2A6MAPT
SCHEMBL29690162 0.66 CYP2C9 (0.50) CYP2C9MAPTKDM4EHPGDALDH1A1
SCHEMBL6893811 0.66 MAOA (0.69) CYP2A6MAPTTP53RXFP1KDM4E
SCHEMBL8984020 0.66 KCNA3 (0.51) CYP2C9KDM4EHSD17B10KMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158810-B2 ALDH-2 inhibitors in the treatment of addiction GILEAD SCIENCES, INC. (US) 2012-04-17 — — US disclosed
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2009-08-20 — — US disclosed
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS AMYGDALA NEUROSCIENCES, INC. 2009-05-14 — — US disclosed
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-08-28 — — US disclosed
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION AMYGDALA NEUROSCIENCES, INC. 2008-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207610-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 C1R 4852/4885NTRK1 909/4885PLK3 3512/4885
US-20090209533-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION ALDH1A1, ADH1A, ALDH3A1 C1R 4852/4885NTRK1 909/4885PLK3 3512/4885
US-20080032995-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION ALDH1A1, ADH1A, ALDH3A1 C1R 4865/4885NTRK1 1031/4885PLK3 2773/4885
US-20090124672-A1 ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS ALDH2, ALDH1A2, ALDH1A1 C1R 4852/4885NTRK1 3159/4885PLK3 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback